Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock Investor Conference presentation 9/26/2019

October 4, 2019 admin Healthcare, Investor Presentations Comments Off on Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock Investor Conference presentation 9/26/2019

Hoth Therapeutics, Inc. (NASDAQ: HOTH)

Next Super Stock investor conference presentation 9/26/2019

Hoth Therapeutics (NASDAQ: HOTH) is targeting multi-billion dollar market opportunities, with it’s pipeline of targeted dermatological therapies for eczema, psoriasis, chronic wound disorders, and acne.

Dermatology is a hot sector, and Pfizer (NYSE: PFE) recently paid $4.9 billion for HOTH peer company, Anacor whose lead product, Eucrisa, is a topical treatment for mild to moderate eczema.

With a shortened path towards regulatory approval, unique technology, and multiple near-term catalysts for value creation, HOTH represents a compelling opportunity. 

Watch this presentation as CEO Robb Knie explain’s HOTH’s unique value proposition for investors.

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.




Related Articles

Healthcare

CytoDyn’s (OTC: CYDY) Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

February 20, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn’s (OTC: CYDY) Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

Based on strong results in its pre-clinical animal study, CytoDyn files for Orphan Drug Designation for Triple-Negative Breast Cancer VANCOUVER, Washington, Feb 20, 2019 – CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized […]

Healthcare

CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

July 1, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

CytoDyn Signs Non-binding Agreement for Diagnostic Licenseand Supply Agreement with IncellDX for PA-14 and/or PRO 140 (non-commercial grade) Collaboration represents an immediate revenue opportunity as a diagnostic test for receptor occupancy and the existence of […]

Healthcare

Zylo and Hoth Therapeutics (NASDAQ: HOTH) Forge Partnership to Develop Endocannabinoid-Based Drug to Treat Lupus

August 29, 2019 admin Healthcare, Newsmakers Comments Off on Zylo and Hoth Therapeutics (NASDAQ: HOTH) Forge Partnership to Develop Endocannabinoid-Based Drug to Treat Lupus

Greenville, SC, Aug. 22, 2019 — Zylo Therapeutics, dedicated to bringing innovative topical technologies to multiple facets of medicine, has entered into a definitive partnership agreement with Hoth Therapeutics (NASDAQ: HOTH) to develop a new treatment for […]